tiprankstipranks
Exelixis (EXEL)
NASDAQ:EXEL
US Market
EXEL
Exelixis
RESEARCH TOOLSreports
Want to see EXEL full AI Analyst Report?

Exelixis (EXEL) Stock Forecast & Price Target

3,174 Followers
See the Price Targets and Ratings of:

EXEL Analyst Ratings

Hold
14Ratings
Hold
4 Buy
9 Hold
1 Sell
Based on 14 analysts giving stock ratings to
Exelixis
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

EXEL Stock 12 Month Forecast

Average Price Target

$51.75
▼(-6.54% Downside)
Based on 14 Wall Street analysts offering 12 month price targets for Exelixis in the last 3 months. The average price target is $51.75 with a high forecast of $64.00 and a low forecast of $41.00. The average price target represents a -6.54% change from the last price of $55.37.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"36":"$36","65":"$65","43.25":"$43.3","50.5":"$50.5","57.75":"$57.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":64,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$64.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":51.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$51.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":41,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$41.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[36,43.25,50.5,57.75,65],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.03,53.87384615384615,54.71769230769231,55.56153846153846,56.40538461538462,57.24923076923077,58.09307692307692,58.93692307692308,59.78076923076923,60.62461538461538,61.46846153846154,62.31230769230769,63.15615384615385,{"y":64,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.03,52.931538461538466,52.83307692307692,52.73461538461539,52.636153846153846,52.53769230769231,52.43923076923077,52.34076923076923,52.24230769230769,52.143846153846155,52.04538461538461,51.94692307692308,51.848461538461535,{"y":51.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.03,52.104615384615386,51.17923076923077,50.253846153846155,49.32846153846154,48.403076923076924,47.47769230769231,46.55230769230769,45.62692307692308,44.70153846153846,43.776153846153846,42.85076923076923,41.925384615384615,{"y":41,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.26,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":37.18,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.2,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.67,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.43,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.83,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.81,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.03,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":44.04,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.68,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.28,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 14, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.96,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.03,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$64.00Average Price Target$51.75Lowest Price Target$41.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on EXEL
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
08/06/26
Guggenheim Keeps Their Hold Rating on Exelixis (EXEL)
Barclays Analyst forecast on EXEL
Etzer Darout
Barclays
Barclays
$49
Hold
-11.50%
Downside
Reiterated
08/06/26
Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
RBC Capital Analyst forecast on EXEL
Leonid Timashev
RBC Capital
RBC Capital
$46
Hold
-16.92%
Downside
Reiterated
08/06/26
RBC Capital Sticks to Their Hold Rating for Exelixis (EXEL)
Wells Fargo Analyst forecast on EXEL
Derek Archila
Wells Fargo
Wells Fargo
$49→$50
Hold
-9.70%
Downside
Assigned
08/06/26
Exelixis (EXEL) Gets a Hold from Wells Fargo
Leerink Partners Analyst forecast on EXEL
Andrew Berens
Leerink Partners
Leerink Partners
$52
Hold
-6.09%
Downside
Downgraded
08/06/26
Exelixis downgraded to Market Perform from Outperform at LeerinkExelixis downgraded to Market Perform from Outperform at Leerink
Truist Financial Analyst forecast on EXEL
Gregory Renza
Truist Financial
Truist Financial
$56→$52
Hold
-6.09%
Downside
Reiterated
08/06/26
Truist Financial Remains a Hold on Exelixis (EXEL)
Morgan Stanley Analyst forecast on EXEL
Sean Laaman
Morgan Stanley
Morgan Stanley
$53
Hold
-4.28%
Downside
Reiterated
08/06/26
Morgan Stanley Sticks to Its Hold Rating for Exelixis (EXEL)
Stifel Nicolaus Analyst forecast on EXEL
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$47→$51
Hold
-7.89%
Downside
Reiterated
08/06/26
Exelixis (EXEL) Receives a Hold from Stifel Nicolaus
William Blair Analyst forecast on EXEL
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (NYSE: DNA), Exelixis (NASDAQ: EXEL) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on EXEL
Yaron Werber
TD Cowen
TD Cowen
$55
Buy
-0.67%
Downside
Reiterated
08/05/26
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
Bank of America Securities Analyst forecast on EXEL
Jason Gerberry
Bank of America Securities
Bank of America Securities
$41
Sell
-25.95%
Downside
Reiterated
08/05/26
Bank of America Securities Reaffirms Their Sell Rating on Exelixis (EXEL)
Goldman Sachs Analyst forecast on EXEL
Paul Choi
Goldman Sachs
Goldman Sachs
$64
Buy
15.59%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)
H.C. Wainwright Analyst forecast on EXEL
Robert Burns
H.C. Wainwright
H.C. Wainwright
$56
Buy
1.14%
Upside
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
UBS Analyst forecast on EXEL
Ashwani Verma
UBS
UBS
$43→$52
Hold
-6.09%
Downside
Assigned
07/02/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)
Jefferies Analyst forecast on EXEL
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$47
Buy
-15.12%
Downside
Reiterated
03/25/26
Jefferies Sticks to Its Buy Rating for Exelixis (EXEL)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Guggenheim Analyst forecast on EXEL
Unknown Analyst
Guggenheim
Not Ranked
Guggenheim
―
Hold
―
Reiterated
08/06/26
Guggenheim Keeps Their Hold Rating on Exelixis (EXEL)
Barclays Analyst forecast on EXEL
Etzer Darout
Barclays
Barclays
$49
Hold
-11.50%
Downside
Reiterated
08/06/26
Barclays Reaffirms Their Hold Rating on Exelixis (EXEL)
RBC Capital Analyst forecast on EXEL
Leonid Timashev
RBC Capital
RBC Capital
$46
Hold
-16.92%
Downside
Reiterated
08/06/26
RBC Capital Sticks to Their Hold Rating for Exelixis (EXEL)
Wells Fargo Analyst forecast on EXEL
Derek Archila
Wells Fargo
Wells Fargo
$49→$50
Hold
-9.70%
Downside
Assigned
08/06/26
Exelixis (EXEL) Gets a Hold from Wells Fargo
Leerink Partners Analyst forecast on EXEL
Andrew Berens
Leerink Partners
Leerink Partners
$52
Hold
-6.09%
Downside
Downgraded
08/06/26
Exelixis downgraded to Market Perform from Outperform at LeerinkExelixis downgraded to Market Perform from Outperform at Leerink
Truist Financial Analyst forecast on EXEL
Gregory Renza
Truist Financial
Truist Financial
$56→$52
Hold
-6.09%
Downside
Reiterated
08/06/26
Truist Financial Remains a Hold on Exelixis (EXEL)
Morgan Stanley Analyst forecast on EXEL
Sean Laaman
Morgan Stanley
Morgan Stanley
$53
Hold
-4.28%
Downside
Reiterated
08/06/26
Morgan Stanley Sticks to Its Hold Rating for Exelixis (EXEL)
Stifel Nicolaus Analyst forecast on EXEL
Stephen Willey
Stifel Nicolaus
Stifel Nicolaus
$47→$51
Hold
-7.89%
Downside
Reiterated
08/06/26
Exelixis (EXEL) Receives a Hold from Stifel Nicolaus
William Blair Analyst forecast on EXEL
Andy Hsieh
William Blair
William Blair
―
Buy
―
Reiterated
08/06/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Ginkgo Bioworks Holdings (NYSE: DNA), Exelixis (NASDAQ: EXEL) and Editas Medicine (NASDAQ: EDIT)
TD Cowen Analyst forecast on EXEL
Yaron Werber
TD Cowen
TD Cowen
$55
Buy
-0.67%
Downside
Reiterated
08/05/26
Exelixis: Buy Rating Reaffirmed on Cabozantinib Resilience, Cost Discipline and Zanzalintinib Upside Despite Near-Term NET Guidance Cut
Bank of America Securities Analyst forecast on EXEL
Jason Gerberry
Bank of America Securities
Bank of America Securities
$41
Sell
-25.95%
Downside
Reiterated
08/05/26
Bank of America Securities Reaffirms Their Sell Rating on Exelixis (EXEL)
Goldman Sachs Analyst forecast on EXEL
Paul Choi
Goldman Sachs
Goldman Sachs
$64
Buy
15.59%
Upside
Reiterated
08/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Eli Lilly & Co (NYSE: LLY), Exelixis (NASDAQ: EXEL) and Moderna (NASDAQ: MRNA)
H.C. Wainwright Analyst forecast on EXEL
Robert Burns
H.C. Wainwright
H.C. Wainwright
$56
Buy
1.14%
Upside
Reiterated
07/02/26
Analysts Offer Insights on Healthcare Companies: Exelixis (NASDAQ: EXEL) and Santhera Pharmaceuticals Holding (Other OTC: SPHDF)
UBS Analyst forecast on EXEL
Ashwani Verma
UBS
UBS
$43→$52
Hold
-6.09%
Downside
Assigned
07/02/26
Analysts Offer Insights on Healthcare Companies: Caris Life Sciences, Inc. (NASDAQ: CAI) and Exelixis (NASDAQ: EXEL)
Jefferies Analyst forecast on EXEL
Unknown Analyst
Jefferies
Not Ranked
Jefferies
$47
Buy
-15.12%
Downside
Reiterated
03/25/26
Jefferies Sticks to Its Buy Rating for Exelixis (EXEL)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
IMMXImmix Biopharma
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Exelixis

3 Months
Robert BurnsH.C. Wainwright
Success Rate
15/19 ratings generated profit
79%
Average Return
+7.92%
Copying Robert Burns's trades and holding each position for 3 Months would result in 78.95% of your transactions generating a profit, with an average return of +7.92% per trade.
1 Year
Robert BurnsH.C. Wainwright
Success Rate
18/19 ratings generated profit
95%
Average Return
+33.92%
Copying Robert Burns's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +33.92% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
18/19 ratings generated profit
95%
Average Return
+52.73%
Copying Robert Burns's trades and holding each position for 2 Years would result in 94.74% of your transactions generating a profit, with an average return of +52.73% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

EXEL Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
0
0
0
0
0
Buy
11
9
8
7
6
Hold
20
17
14
15
18
Sell
1
0
1
1
2
Strong Sell
0
0
0
0
0
total
32
26
23
23
26
In the current month, EXEL has received 6 Buy Ratings, 18 Hold Ratings, and 2 Sell Ratings. EXEL average Analyst price target in the past 3 months is 51.75.
Each month's total comprises the sum of three months' worth of ratings.

EXEL Financial Forecast

EXEL Earnings Forecast

Next quarter’s earnings estimate for EXEL is $0.89 with a range of $0.76 to $0.96. The previous quarter’s EPS was $0.91. EXEL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EXEL has Performed in-line its overall industry.
Next quarter’s earnings estimate for EXEL is $0.89 with a range of $0.76 to $0.96. The previous quarter’s EPS was $0.91. EXEL beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year EXEL has Performed in-line its overall industry.

EXEL Sales Forecast

Next quarter’s sales forecast for EXEL is $651.42M with a range of $636.20M to $672.00M. The previous quarter’s sales results were $628.69M. EXEL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EXEL has Performed in-line its overall industry.
Next quarter’s sales forecast for EXEL is $651.42M with a range of $636.20M to $672.00M. The previous quarter’s sales results were $628.69M. EXEL beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year EXEL has Performed in-line its overall industry.

EXEL Stock Forecast FAQ

What is EXEL’s average 12-month price target, according to analysts?
Based on analyst ratings, Exelixis’s 12-month average price target is 51.75.
    What is EXEL’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for EXEL, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is EXEL a Buy, Sell or Hold?
        Exelixis has a consensus rating of Hold which is based on 4 buy ratings, 9 hold ratings and 1 sell ratings.
          What is Exelixis’s price target?
          The average price target for Exelixis is 51.75. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst price target is $64.00 ,the lowest forecast is $41.00. The average price target represents -6.54% Decrease from the current price of $55.37.
            What do analysts say about Exelixis?
            Exelixis’s analyst rating consensus is a Hold. This is based on the ratings of 14 Wall Streets Analysts.
              How can I buy shares of EXEL?
              Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.